ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03311477
Recruitment Status : Recruiting
First Posted : October 17, 2017
Last Update Posted : April 3, 2018
Sponsor:
Information provided by (Responsible Party):
AbbVie

Brief Summary:
An open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-399 in participants with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Cancer - Solid Tumors Drug: ABBV-399 Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study to Evaluate the Safety and Pharmacokinetics of ABBV-399 in Japanese Subjects With Advanced Solid Tumors
Actual Study Start Date : November 6, 2017
Estimated Primary Completion Date : June 19, 2019
Estimated Study Completion Date : June 19, 2019

Arm Intervention/treatment
Experimental: ABBV-399
ABBV-399 via intravenous administration at escalating dose levels.
Drug: ABBV-399
Intravenous infusion



Primary Outcome Measures :
  1. Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t) [ Time Frame: Up to 24 months ]
    AUC (0-t) is defined as area under the concentration versus time curve from time zero (pre-dose) to the time of the last measurable concentration.

  2. Maximum Tolerated Dose (MTD) or maximally administered dose (MAD) for ABBV-399 [ Time Frame: Up to 21 days ]
    MTD/MAD is defined as the highest dose level at which less than 2 of 6 (or < 33% if cohort is expanded beyond 6) participants experience a dose limiting toxicity.

  3. Terminal elimination half life (t1/2) [ Time Frame: Up to 24 months ]
    Terminal elimination half life (t1/2)

  4. Maximum Observed Concentration (Cmax) [ Time Frame: Up to 24 months ]
    Maximum observed concentration (Cmax)

  5. Time to Cmax (Tmax) [ Time Frame: Up to 24 months ]
    Time to Cmax (Tmax)


Secondary Outcome Measures :
  1. Progression-Free Survival (PFS) Time [ Time Frame: Up to 24 months ]
    PFS time is defined as the time from the participant's first dose of ABBV-399 to either the participant's disease progression or death, whichever occurs first.

  2. Objective Response Rate (ORR) [ Time Frame: Up to 24 months ]
    Objective response rate (ORR) is defined as the proportion of participants with a confirmed partial or complete response to the treatment. Evaluation of tumor response is based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

  3. Duration of response (DOR) [ Time Frame: Up to 24 months ]
    DOR is defined as the time from the participant's initial objective response to study drug therapy to disease progression or death, whichever occurs first.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant with histologically confirmed advanced solid tumor.
  • Participant must have advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit.
  • Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
  • Participant must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  • Participant has archived diagnostic formalin-fixed paraffin embedded (FFPE) tumor tissue available for analysis.
  • Participant has adequate bone marrow, renal, and hepatic function.

Exclusion Criteria:

  • Participant has received anticancer therapy including chemotherapy, immunotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within a period of 21 days, or herbal therapy within 7 days prior to the first dose of ABBV-399.
  • Participant has known uncontrolled metastases to the central nervous system. Participants with brain metastases are eligible after definitive therapy provided they are asymptomatic off systemic steroids and anticonvulsants for at least 2 weeks prior to first dose of ABBV-399.
  • Participant has unresolved clinically significant adverse events >= Grade 2 from prior anticancer therapy except for alopecia or anemia.
  • Participant has had major surgery within 21 days prior to the first dose of ABBV-399.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03311477


Contacts
Contact: AbbVie GK Clinical Trial Registration Desk +81-3-4577-1111 abbvie_jpn_info_clingov@abbvie.com

Locations
Japan
Shizuoka Cancer Center Recruiting
Sunto-gun, Shizuoka, Japan, 411-8777
National Cancer Center Hosp Recruiting
Chuo-ku, Tokyo, Japan, 104-0045
Sponsors and Collaborators
AbbVie
Investigators
Study Director: AbbVie Inc. AbbVie

Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT03311477     History of Changes
Other Study ID Numbers: M16-080
First Posted: October 17, 2017    Key Record Dates
Last Update Posted: April 3, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by AbbVie:
ABBV-399
Maximum tolerated dose (MTD)
Maximally administered dose (MAD)
Dose escalation
Pharmacokinetics
Advanced solid tumors
Cancer
Solid tumors

Additional relevant MeSH terms:
Neoplasms